Clinical analysis of valproic acid combined with all-trans retinoic acid in the treatment of myelodysplastic syndrome / 白血病·淋巴瘤

ABSTRACT

Objective To evaluate the efficacy and safety of valproic acid combined with all-trans retinoic acid(ATRA) in the treatment of myelodysplastic syndrome. Methods Twenty-two patients with MDS consisting of 4 RA, 1 RARS, 10 RCMD, 1 RCMD-RS, 3 RAEB-1 and 3 RAEB-2 were analyzed. The initial dose of valproic acid was 0.6 g/d, then increased to 1.2 g/d after one week; all-trans retinoic acid was administered at 30 mg/d every other week after taken VPA one week later. All patients maintained treatment for 3 months unless severe side effect was found or disease progression. Bone marrow examination was taken every 4 weeks. Results The response rate was 27.3 % (6 cases) according to International Working Group (IWG) criteria, no patient achieved completely remission(CR), 2 cases achieved partial remission(PR), 4 case achieved hematologic improvement(HI), 9 cases was stable and 7 cases was failure. Most of these cases had slight adverse events and could be tolerated. Conclusion Valproic acid combined with all-trans retinoic acid in the treatment of patients with myelodysplastic syndrome was efficient and side effect was tolerable.